Results 101 to 110 of about 4,608 (197)

COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET [PDF]

, 2018
Marianne Pavel, Anja Rinke, Richard P. Baum   +2 more
openalex   +1 more source

PRRT plus holmium‐166‐SIRT (HEPAR PLuS) versus PRRT‐only in patients with metastatic neuroendocrine tumors: A propensity‐score matched analysis

Journal of Neuroendocrinology
AbstractPatients with bulky neuroendocrine liver metastases (NELM) undergoing PRRT with [177Lu]Lu‐DOTATATE have a worse survival than patients with limited liver metastases. Previously, the safety and efficacy of additional selective internal radiotherapy (SIRT), using holmium‐166 (166Ho)‐microspheres, directly following PRRT in patients with NELM were
Veldhuis, W., Walter, Thomas, de Vries-Huizing, D., Theysohn, J., Barton, S., Ekkelenkamp, E., Lachachi, B., de Jong, R., van Golen, L., Lanzafame, H., Milot, L., Lahner, H., Lam, M., Tesselaar, M., Braat, A.   +14 more
openaire   +2 more sources

Metachronous occurrence of acute myeloid leukaemia in a case of neuroendocrine tumour

European Journal of Case Reports in Internal Medicine
Haematological neoplasms are rare in patients undergoing peptide receptor radionuclide therapy (PRRT) for neuroendocrine neoplasms, though the long-term effects on bone marrow function remain an area of interest.
Abhinav Menon, Dilip Harindran Vallathol, Deepak Charles, Shagos Nair, Karthika Kundil Veetil, Ashok S. Komaranchath, Arun R. Warrier   +6 more
doaj   +1 more source

The Use of 99mTc-HYNIC-TOC and 18F-FDG PET/CT in the Evaluation of Duodenal Neuroendocrine Tumor with Atypical and Extensive Metastasis Responding Dramatically to a Single Fraction of PRRT with 177Lu-DOTATATE [PDF]

, 2014
Sandip Basu, Anuja Abhyankar
openalex   +1 more source

Comparison of the Hematotoxicity of PRRT with Lutathera® and Locally Manufactured 177Lu-HA-DOTATATE in Patients with Neuroendocrine Tumors and the Impact of Different Application Intervals [PDF]

Markus Hofmann, Sophie C. Kunte, Marcus Unterrainer, Astrid Delker, Adrien Holzgreve, Johannes Toms, F.J. Gildehaus, Christoph J. Auernhammer, Christine Spitzweg, Mathias J. Zacherl, Harun Ilhan, Johannes Rübenthaler, Leonie Beyer, Lena M. Unterrainer   +13 more
openalex   +1 more source

P06.04 * PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) WITH 90Y-DOTATOC TARGETING OF RECURRENT ATYPICAL MENINGIOMA: A CASE REPORT [PDF]

, 2014
Sarah Iglseder, Martha Nowosielski, Armin Muigg, Günther Stockhammer, Christian F. Freyschlag, Johannes Lanbach, Meinhard Nevinny‐Stickel, Sabine Buxbaum, Christian Uprimny, Irene Virgolini   +9 more
openalex   +1 more source

1186MO A prospective phase II single-arm trial on neoadjuvant peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE followed by surgery for pancreatic neuroendocrine tumors (NeoLuPaNET) [PDF]

, 2023
Stefano Partelli, Luca Landoni, Mirco Bartolomei, Alessandro Zerbi, Chiara Maria Grana, Ugo Boggi, Giovanni Butturini, Riccardo Casadei, Claudio Bassi, Massimo Falconi   +9 more
openalex   +1 more source

Atypical Metastatic Disease in Thyroid from Pancreatic Neuroendocrine Tumor and its Response to [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT): A Promising Therapeutic Option for Somatostatin Receptor Expressing Unusual Metastatic Sites [PDF]

Mali Madhava Reddy, Rahul V. Parghane, Sandip Basu   +2 more
openalex   +1 more source

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT [PDF]

, 2018
Michela Del Prete, Frédéric Arsenault, Nassim Saighi, Wei Zhao, François-Alexandre Buteau, A. Ćeller, Jean‐Mathieu Beauregard   +6 more
openalex   +1 more source

Metastatic Malignant Paraganglioma of Rare Sites Failed on Conventional Treatments Demonstrating Beneficial Response to 177Lu-DOTATATE PRRT [PDF]

Yeshwanth Edamadaka, Munita Bal, Swapnil Rane, Rahul V. Parghane, Sandip Basu   +4 more
openalex   +1 more source